Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TC Biopharm (Holdings) PLC TCBP

Healthcare Biotechnology
TC BioPharm (Holdings) plc, formerly TC BioPharm (Holdings) Limited, is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapy products that are based on its allogeneic gamma delta T (GD-T) cell platform. Harnessing the innate ability of GD-Ts, the Company has developed a range of clinical-stage cell therapies designed to combat identified cancers and viral infections. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, it is also developing a range of genetically modified chimeric antigen receptor modified T cell (CAR-T) products for treatment of solid cancers. The Company’s pipeline includes OmnImmune, ImmuniStim, TCB009, and TCB005/TCB006. OmnImmune is an allogeneic unmodified GD-T (GD-T2) cell product, used for the treatment of Acute Myeloid Leukaemia (AML). ImmuniStim is used for the treatment of coronavirus disease (COVID-19). TCB009 is developing GD-T2 based cell therapies.


NDAQ:TCBP - Post by User

TC Biopharm (Holdings) PLC
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(291)
•••
Post by whytestockson May 06, 2024 10:15am
50 Views
Post# 36024777

TC BioPharm Announces Execution of Second Non-Binding Letter

TC BioPharm Announces Execution of Second Non-Binding Letter
BREAKING NEWS: $TCBP TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T TherapiesTC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies PR Newswire Acquisition target has established proof of concept data demonstrating the therapeutic potential for the treatment of multiple solid tum...TCBP - TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities